<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332017000300269</article-id>
<article-id pub-id-type="doi">10.1016/j.rccar.2016.09.012</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Duración de la antiagregación dual postintervencionismo percutáneo]]></article-title>
<article-title xml:lang="en"><![CDATA[Duration of dual antiaggregation therapy after percutaneous intervention]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montoya Roldán]]></surname>
<given-names><![CDATA[Daniel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez Cano]]></surname>
<given-names><![CDATA[Carlos A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodas]]></surname>
<given-names><![CDATA[Luisa María Parra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Pontificia Bolivariana  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Clínica CardioVID Departamento de Cardiología ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Pontificia Bolivariana  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>24</volume>
<numero>3</numero>
<fpage>269</fpage>
<lpage>276</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332017000300269&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332017000300269&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332017000300269&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  Con el uso de stents medicados de primera generación, el riesgo de trombosis es de 1,9% a 18 meses, con consecuencias que suelen ser graves y potencialmente fatales. La antiagregación doble, que previene tal efecto, conlleva un riesgo de sangrado que se incrementa según la duración de la misma, por tanto, tratar de alcanzar el equilibrio entre riesgo y beneficio es el objetivo primordial.  Objetivo:  Presentar la evidencia actual sobre la duración óptima de la doble antiagregación y brindar pautas para establecer cuál debe ser esta para los pacientes. La antiagregación doble busca evitar el riesgo de trombosis temprana y reducir los eventos coronarios no relacionados con el inicial, sobre todo en pacientes con alto riesgo de eventos cardiovasculares o trombosis tardía. La terapia de corta duración puede ser una alternativa más segura que el estándar de un año y sin diferencia en eficacia en pacientes de bajo riesgo cardiovascular. La antiagregación de larga duración disminuye la trombosis del stent y los eventos coronarios, pero puede incrementar el riesgo de sangrado clínicamente importante.  Conclusiones:  Hasta hoy la literatura no permite definir un tiempo ideal para la antiagregación dual; este debe definirse para cada caso en particular.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  With the use of first-generation drug-eluting stents, the risk of thrombosis is of 1.9% at 18 months, with consequences that are usually severe and are potentially fatal. Dual antiaggregation therapy, that prevents such effects, entails a bleeding risk that is increased according to its duration, therefore, trying to achieve a balance between risk and benefit is the key goal.  Objective:  To present current evidence of the optimal duration of dual antiaggregation therapy and to provide guidelines to establish the duration for patients. Dual antiaggregation therapy seeks to avoid the risk of early thrombosis and to reduce coronary events not related to the initial one, specially in patients with high risk of cardiovascular events or late thrombosis. Short duration therapy can be a safer alternative than the standard of one year and without a difference in patients with low cardiovascular risk. Long duration antiaggregation therapy reduces the risk of stent thrombosis and coronary events, but can increase the risk of a clinically important bleeding.  Conclusions:  Until today literature does not allow to define an ideal time for dual antiaggregation therapy; this must be defined according to each particular case.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Stents]]></kwd>
<kwd lng="es"><![CDATA[Stents liberadores de fármacos]]></kwd>
<kwd lng="es"><![CDATA[Inhibidores de agregación plaquetaria]]></kwd>
<kwd lng="en"><![CDATA[Stents]]></kwd>
<kwd lng="en"><![CDATA[Drug-eluting stents;Platelet aggregation Inhibitors]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Airoldi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Colombo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morici]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Latib]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cosgrave]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Buellesfeld]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2007</year>
<volume>116</volume>
<page-range>745-54</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Harchandani]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-eluting stents the past, present, and future]]></article-title>
<source><![CDATA[Curr Atheroscler Rep]]></source>
<year>2015</year>
<volume>17</volume>
<page-range>485</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lagerqvist]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Stenestrand]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Lindbäck]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nilsson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wallentin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2007</year>
<volume>356</volume>
<page-range>1009-19</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ariotti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Valgimigli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk navigating between limited evidence and clinical concerns]]></article-title>
<source><![CDATA[Curr Opin Cardiol]]></source>
<year>2015</year>
<volume>30</volume>
<page-range>325-32</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palmerini]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Stone]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation conceptual evolution based on emerging evidence]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2016</year>
<volume>37</volume>
<page-range>353-64</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Binder]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Lüscher]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Duration of dual antiplatelet therapy after coronary artery stenting where is the sweet spot between ischaemia and bleeding?]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2015</year>
<volume>36</volume>
<page-range>1207-11</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mauri]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kereiakes]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Driscoll-Shempp]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cutlip]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Steg]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>371</volume>
<page-range>2155-66</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
<name>
<surname><![CDATA[Bates]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Bittl]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Brindis]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Fihn]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Fleisher]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of STElevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Gara]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
<name>
<surname><![CDATA[Kushner]]></surname>
<given-names><![CDATA[FG]]></given-names>
</name>
<name>
<surname><![CDATA[Ascheim]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[de Lemos]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions]]></article-title>
<source><![CDATA[Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv]]></source>
<year>2013</year>
<volume>82</volume>
<page-range>E1-27</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<collab>Task Force Members.Montalescot G.Sechtem U.Achenbach S.Andreotti F.Arden C</collab>
<article-title xml:lang=""><![CDATA[2013 ESC guidelines on the management of stable coronary artery disease the Task Force on the management of stable coronary artery dise ase of the European Society of Cardiology]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2013</year>
<volume>34</volume>
<page-range>2949-3003</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roffi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Patrono]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Collet]]></surname>
<given-names><![CDATA[J-P]]></given-names>
</name>
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Valgimigli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Andreotti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2016</year>
<volume>37</volume>
<page-range>267-315</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feres]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Abizaid]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Leon]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Marin-Neto]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Botelho]]></surname>
<given-names><![CDATA[RV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents the OPTIMIZE randomized trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2013</year>
<volume>310</volume>
<page-range>2510-22</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[B-K]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[M-K]]></given-names>
</name>
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[D-H]]></given-names>
</name>
<name>
<surname><![CDATA[Nam]]></surname>
<given-names><![CDATA[C-M]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[J-S]]></given-names>
</name>
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[Y-G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new strategy for discontinuation of dual antiplatelet therapy the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2012</year>
<volume>60</volume>
<page-range>1340-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valgimigli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Campo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Monti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vranckx]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Percoco]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tumscitz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting a randomized multicenter trial]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2012</year>
<volume>125</volume>
<page-range>2015-26</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gwon]]></surname>
<given-names><![CDATA[H-C]]></given-names>
</name>
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[J-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[YB]]></given-names>
</name>
<name>
<surname><![CDATA[Chae]]></surname>
<given-names><![CDATA[I-H]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[D-S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2012</year>
<volume>125</volume>
<page-range>505-13</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palmerini]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sangiorgi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Valgimigli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Biondi-Zoccai]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Feres]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Abizaid]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation an individual patient data pairwise and network meta-analysis]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2015</year>
<volume>65</volume>
<page-range>1092-102</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elmariah]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mauri]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Doros]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Galper]]></surname>
<given-names><![CDATA[BZ]]></given-names>
</name>
<name>
<surname><![CDATA[O'Neill]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Steg]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extended duration dual antiplatelet therapy and mortality a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Lancet Lond Engl]]></source>
<year>2015</year>
<volume>385</volume>
<page-range>792-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giustino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Baber]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Sartori]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mehran]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mastoris]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kini]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Duration of dual antiplatelet therapy after drug-eluting stent implantation a systematic review and metaanalysis of randomized controlled trials]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2015</year>
<volume>65</volume>
<page-range>1298-310</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palmerini]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Benedetto]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Bacchi-Reggiani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Della Riva]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Biondi-Zoccai]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Feres]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality in patients treated with extended duration dual antiplatelet therapy afterdrug-eluting stent implantation a pairwise and Bayesian network meta-analysis of randomised trials]]></article-title>
<source><![CDATA[Lancet Lond Engl]]></source>
<year>2015</year>
<volume>385</volume>
<page-range>2371-82</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Helft]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Steg]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Le Feuvre]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Georges]]></surname>
<given-names><![CDATA[J-L]]></given-names>
</name>
<name>
<surname><![CDATA[Carrie]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dreyfus]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stopping or continuing clopidogrel 12 months after drug-eluting stent placement the OPTIDUAL randomized trial]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2016</year>
<volume>37</volume>
<page-range>365-74</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Secemsky]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Kereiakes]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Normand]]></surname>
<given-names><![CDATA[S-LT]]></given-names>
</name>
<name>
<surname><![CDATA[Gershlick]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention.]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dewilde]]></surname>
<given-names><![CDATA[WJM]]></given-names>
</name>
<name>
<surname><![CDATA[Oirbans]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Verheugt]]></surname>
<given-names><![CDATA[FWA]]></given-names>
</name>
<name>
<surname><![CDATA[Kelder]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[De Smet]]></surname>
<given-names><![CDATA[BJGL]]></given-names>
</name>
<name>
<surname><![CDATA[Herrman]]></surname>
<given-names><![CDATA[J-P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention an open-label, randomised, controlled trial]]></article-title>
<source><![CDATA[Lancet Lond Engl.]]></source>
<year>2013</year>
<volume>381</volume>
<page-range>1107-15</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fiedler]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Maeng]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mehilli]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schulz-Schüpke]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Byrne]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Sibbing]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation The ISAR-TRIPLE Trial]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2015</year>
<volume>65</volume>
<page-range>1619-29</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[C-F]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Y-Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment A meta-analysis]]></article-title>
<source><![CDATA[Herz]]></source>
<year>2015</year>
<volume>40</volume>
<page-range>1070-83</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
